We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancers and infectious disease.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics to Present Clinical Data at Upcoming Oncology Medical Conferences

    Data to highlight SNS-301, a first-in-class cancer immunotherapy targeting ASPH, a novel tumor-specific antigen GAITHERSBURG, Md.--( BUSINESS WIRE )-- Sensei Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company discovering and developing precision immuno-oncology therapies, todayRead More

  • Sensei Biotherapeutics Appoints Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer

    Sensei CMO Ildiko Csiki (Photo: Business Wire) August 21, 2018 08:00 AM Eastern Daylight Time GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical company developing immuno-oncology therapies that teach the immune system to recognize and attackRead More

  • Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301

    SNS-301 demonstrated a strong safety profile and promising immune responses in patients with biochemically recurrent prostate cancer SNS-301 is a first-in-class immunotherapy candidate emerging from Sensei’s SPIRIT platform that targets a novel embryonic antigen found on more than 20 types ofRead More

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics to Present Clinical Data at Upcoming Oncology Medical Conferences

    Data to highlight SNS-301, a first-in-class cancer immunotherapy targeting ASPH, a novel tumor-specific antigen GAITHERSBURG, Md.--( BUSINESS WIRE )-- Sensei Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company discovering and developing precision immuno-oncology therapies, todayRead More

  • Sensei Biotherapeutics Appoints Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer

    Sensei CMO Ildiko Csiki (Photo: Business Wire) August 21, 2018 08:00 AM Eastern Daylight Time GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical company developing immuno-oncology therapies that teach the immune system to recognize and attackRead More

  • Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301

    SNS-301 demonstrated a strong safety profile and promising immune responses in patients with biochemically recurrent prostate cancer SNS-301 is a first-in-class immunotherapy candidate emerging from Sensei’s SPIRIT platform that targets a novel embryonic antigen found on more than 20 types ofRead More

Signup For Update

sign up for newsletter and get the latest update